ObesityPhase 2NCT07030868

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

A Phase 2 study testing LY3549492 in people with Obesity and Overweight, run by Eli Lilly and Company at 42 sites in 2 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months. Read more about this study

Who is it for?: Ages 18 to 75 years
Conditions the study is for: Obesity, Overweight, Type 2 Diabetes
What is being tested?: LY3549492
Type of treatment: Pill or oral medicine
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 1 participants
Where: 42 sitesin 2 countries
Study dates: 19 Jun 2025to 29 Jul 2025
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

W8M-MC-GN02:
Assigned male at birth
Assigned female at birth, who are of non-childbearing potential
Have type 2 diabetes
W8M-MC-CWMM:
Have a BMI ≥27 kilograms per square meter (kg/m²)
Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss

Who cannot join

W8M-MC-GN02:
Individuals who are of childbearing potential
Have a history of acute or chronic pancreatitis
Have any of the following cardiovascular conditions within 6 months prior to screening:
acute myocardial infarction
cerebrovascular accident (stroke)

Show all 15Show fewer

unstable angina, or
hospitalization due to congestive heart failure.
W8M-MC-CWMM:
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma
Have poorly controlled hypertension
Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease
Have a history of symptomatic gallbladder disease within the past 2 years
Have a lifetime history of suicide attempts

Trial locations and contacts

42 sites in 2 countries.

Country

City, postcode or hospital

42 sites in 2 countries

United States38 sites

Medical Research Partners
Ammon, Idaho, 83406
IMA Clinical Research Austin
Austin, Texas, 78745
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640
Velocity Clinical Research, Dallas
Dallas, Texas, 75230
FutureSearch Trials of Dallas
Dallas, Texas, 75251
Spectrum Medical, Inc.
Danville, Virginia, 24541
Velocity Clinical Research, Syracuse
East Syracuse, New York, 13057
Northeast Research Institute (NERI)
Fleming Island, Florida, 32003
NorCal Medical Research, Inc
Greenbrae, California, 94904
Indago Research & Health Center, Inc
Hialeah, Florida, 33012
PlanIt Research, PLLC
Houston, Texas, 77079
Velocity Clinical Research, Huntington Park
Huntington Park, California, 90255
Las Vegas Medical Research
Las Vegas, Nevada, 89128
New Horizon Research Center
Miami, Florida, 33165
Monroe Biomedical Research
Monroe, North Carolina, 28112
Lucas Research, Inc
Morehead City, North Carolina, 28557
Quality Medical Research
Nashville, Tennessee, 37211
Knownwell
Needham, Massachusetts, 02492
Lucida Clinical Trials
New Bedford, Massachusetts, 02740
Lucas Research, Inc.
New Bern, North Carolina, 28562
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Charter Research - Winter Park
Orlando, Florida, 32803
HOPE Research Institute
Phoenix, Arizona, 85032
Rochester Clinical Research, LLC
Rochester, New York, 14609
Peninsula Research Associates
Rolling Hills Estates, California, 90274
Tekton Research - Fredericksburg Road
San Antonio, Texas, 78229
Endeavor Clinical Trials
San Antonio, Texas, 78240
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260
Headlands Research - Detroit
Southfield, Michigan, 48034
Clinvest Headlands Llc
Springfield, Missouri, 65807
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905
Charter Research - Lady Lake
The Villages, Florida, 32162
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, 98801
Texas Valley Clinical Research
Weslaco, Texas, 78596
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50266

Other trials in United States

Argentina4 sites

Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., C1120AAC
Consultorio de Investigación Clínica EMO SRL
Buenos Aires, Buenos Aires F.D., C1405BUB
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., C1425AGC
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, C1056ABI

Other trials in Argentina

About this study

Official title: A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)

Participation in the study will last about 11 months.

Conditions: Obesity, Overweight, Type 2 Diabetes
Being tested: LY3549492, Placebo
Medical subject headings: Obesity, Overweight, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

LY3549492Drug
Administered orally
PlaceboDrug
Administered orally

Study groups in NCT07030868
Study group	Role	What they receive
LY3549492 Low Dose	Experimental	Participants will receive LY3549492 orally Receives: Drug: LY3549492
LY3549492 High Dose with Fast Titration	Experimental	Participants will receive LY3549492 orally Receives: Drug: LY3549492
LY3549492 High Dose with Slow Titration	Experimental	Participants will receive LY3549492 orally Receives: Drug: LY3549492
Placebo	Placebo comparator	Participants will receive placebo orally Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Percent Change From Baseline in Body Weight
Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.
Measured: Baseline, Week 32

Secondary outcomes (5)

Change From Baseline in Body Weight
Change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and absolute change from baseline was to be calculated.
Measured: Baseline, Week 32
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Percentage of participants who achieved at least 5% reduction in body weight from baseline to Week 32.
Measured: Baseline, Week 32
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of participants who achieved at least 10% reduction in body weight from baseline to Week 32.
Measured: Baseline, Week 32
Change From Baseline in Hemoglobin A1c (HbA1c)
Change from baseline in hemoglobin A1c (HbA1c) at Week 32. HbA1c was intended to be measured as a percentage and reflects average blood glucose levels over approximately 3 months.
Measured: Baseline, Week 32
Pharmacokinetics (PK): Average Concentration of LY3549492
Average plasma concentration of LY3549492. Pharmacokinetic samples were intended to be collected at multiple timepoints, including pre-dose and post-dose intervals, to evaluate the pharmacokinetic profile of LY3549492 over time.
Measured: Week 0 and Week 24 (6-18 hours post-dose); Weeks 3, 9, 15, and 18 (1-3 hours post-dose); Weeks 6 and 21 (3-6 hours post-dose); Week 12 (1-6 hours post-dose); and Weeks 30 and 32 (pre-dose).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

19 Jun 202529 Jul 2025

First posted22 Jun 2025
Study start19 Jun 2025
Primary completion29 Jul 2025
Study completion29 Jul 2025

Why it stopped: Study terminated for strategic business reasons

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for ObesityStudies of the same condition, open and under way.
More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 1 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07030868
Sponsor's protocol ID: 27321
Other IDs: W8M-MC-GN02, W8M-MC-CWMM
Status last verified: Aug 2026
First submitted: 13 Jun 2025
Last updated: 31 Aug 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)

All Obesity trials

Study at a glance

From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)
ClinicalTrials.gov ID: NCT07030868
Acronym / sponsor ID: 27321
Conditions: Obesity, Overweight, Type 2 Diabetes
Phase: Phase 2
Study type: Interventional
Recruitment status: TerminatedReason stopped: Study terminated for strategic business reasons
Enrolment: 1 participants (actual)
Lead sponsor: Eli Lilly and CompanyIndustry (pharma, biotech, devices)
Study start: 19 Jun 2025 (actual)
Primary completion: 29 Jul 2025 (actual)
Study completion: 29 Jul 2025 (actual)
First posted: 22 Jun 2025 (actual)
Results: Posted 31 Aug 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Participation in the study will last about 11 months.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 4

Arm	Type	Receives
LY3549492 Low Dose	Experimental	Drug: LY3549492Participants will receive LY3549492 orally
LY3549492 High Dose with Fast Titration	Experimental	Drug: LY3549492Participants will receive LY3549492 orally
LY3549492 High Dose with Slow Titration	Experimental	Drug: LY3549492Participants will receive LY3549492 orally
Placebo	Placebo comparator	Drug: PlaceboParticipants will receive placebo orally

Who may qualify

Ages: 18 to 75 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

Assigned male at birth
Assigned female at birth, who are of non-childbearing potential
Have type 2 diabetes
Have a BMI ≥27 kilograms per square meter (kg/m²)
Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss

Key exclusion criteria (15 listed)

Individuals who are of childbearing potential
Have a history of acute or chronic pancreatitis
Have any of the following cardiovascular conditions within 6 months prior to screening:
Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
LY3549492Administered orally	Drug	LY3549492 High Dose with Fast Titration, LY3549492 High Dose with Slow Titration, LY3549492 Low Dose
PlaceboAdministered orally	Drug	Placebo

Primary outcome

Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 32
Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.

5 secondary outcomes

Change From Baseline in Body Weight
Time frame: Baseline, Week 32
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Time frame: Baseline, Week 32
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Time frame: Baseline, Week 32
Change From Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 32
Pharmacokinetics (PK): Average Concentration of LY3549492
Time frame: Week 0 and Week 24 (6-18 hours post-dose); Weeks 3, 9, 15, and 18 (1-3 hours post-dose); Weeks 6 and 21 (3-6 hours post-dose); Week 12 (1-6 hours post-dose); and Weeks 30 and 32 (pre-dose).

Results and safety

Results posted to the registry on 31 Aug 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
LY3549492 or Placebo (Randomised, Not Treated)	1	0

Primary outcome: Percent Change From Baseline in Body Weight

Time frame: Baseline, Week 32

Population analysed: The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures data was collected and no analyses could be performed.

5 secondary outcomes are reported in the full results.

Adverse events

Time frame: All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
LY3549492 or Placebo (Randomised, Not Treated)	0 of 0	0 of 0	0

Limitations and caveats (from the sponsor): The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected, and no analyses could be performed.

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesLink provided by the sponsor.
Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Related trials for Obesity

RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director

Eli Lilly and Company

42 sites in 2 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing LY3549492 in people with Obesity and Overweight, run by Eli Lilly and Company at 42 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 42 sites in United States, Argentina. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent Change From Baseline in Body Weight (time frame: Baseline, Week 32). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07030868.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.